{"id":15278,"date":"2012-03-09T16:35:58","date_gmt":"2012-03-09T15:35:58","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=15278"},"modified":"2012-03-09T16:39:03","modified_gmt":"2012-03-09T15:39:03","slug":"deborah-cohen-access-to-nice-approved-drugs","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/","title":{"rendered":"Deborah Cohen: Access to NICE approved drugs"},"content":{"rendered":"

\"DeborahIn the midst of his heavy schedule, defending his controversial NHS reforms, Andrew Lansley, health secretary for England,\u00a0has found the time to form a new expert panel which will contribute to a government report on the NHS Constitution.<\/p>\n

This will set out in one place what patients can expect from the NHS, including rights:<\/p>\n

\u2022\u00a0to be treated with respect and humanity
\n\u2022\u00a0to have access to NICE-approved drugs
\n\u2022\u00a0to make choices about their NHS care<\/p>\n

There\u2019s very little here that few people could argue with\u2013that people are treated with decency and their choices about their care are respected. What’s interesting is the middle option\u2014that patients should have access to NICE approved drugs. It seems perfectly logical at first sight\u2014a way around the so-called postcode lottery.<\/p>\n

But it\u2019s exactly this that representatives of the drug industry have been lobbying for. Such a stance might sound like companies are softening on a previously hostile relationship with NICE\u2014an organisation seen to prevent the rapid uptake of new drugs.<\/p>\n

At an ABPI meeting last year, Ramona Sequeira, managing director of Lilly UK, stated that patients also need better access to NICE approved drugs.\u00a0<\/p>\n

There is an industry view that UK doctors are conservative in their prescribing patterns and medicines are not prescribed once NICE have given them the green light. Commissioners tend to go for generics. As Ms Sequeira put it the UK only spends 0.9% of GDP on medicines compared to 1.2% in the rest of EU.<\/p>\n

“The NHS is very good at the uptake of old and very cheap technology. The uptake of innovation is a problem in the UK,” Paul Catchpole, value and access director, of the ABPI,\u00a0said<\/a>.\u00a0<\/p>\n

Today, a PharmaTimes Director\u2019s Club event <\/a>at the King\u2019s Fund health charity\u00a0will argue that “there is real and present industry concern that the medical management community is over-focused on medicine costs rather than health outcomes.”\u00a0 A new report called ‘The Innovation Health and Wealth – Accelerating Adoption and Diffusion in the NHS<\/em>‘ will highlight these concerns.<\/p>\n

The push for NICE approved drugs is a clever drug industry move and one that seems to have paid off.<\/p>\n

\u00a0And it\u2019s a global tactic too. Lobbying by the Japanese government on behalf of the drug industry in the build up to the UN summit on non-communicable diseases in New York last September<\/a> urged the use of “high quality\u201d medicines\u2014a reference to branded as opposed to generic drugs. They also pushed for \u201cacknowledged public health best practices,\u201d as opposed to cost effective interventions.<\/p>\n

But it is worth thinking about what the right to guaranteed access to NICE approved drugs might mean for a cash-strapped NHS.<\/p>\n

NICE approves lots of drugs that aren’t always the best or most cost-effective option for certain conditions. In many cases the “new” more expensive version might be the best of the lot\u2013but in many cases the benefit is marginal and not worth the cost<\/p>\n

For example, NICE has given the nod to both analogue and human insulin. However, analogue insulin is far more expensive than human insulin and NICE guidance\u2014produced alongside drug appraisals\u2014 says that analogue should only be used in defined circumstances in type 2 diabetes.<\/p>\n

A paper in BMJ Open<\/em><\/a> concluded that given the high marginal cost of analogue insulin, adherence to prescribing guidelines recommending the preferential use of human insulin would have resulted in considerable financial savings over the period. It estimated that if all patients using insulin analogues could have received human insulin instead, the overall incremental cost of analogue insulin was \u00a3625 million.<\/p>\n

So where would that leave doctors who follow NICE guidance? It would leave doctors vulnerable to concerted campaigns by some industry funded patients groups who argue for the latest treatment\u2014even if the evidence base does not support its preferential use. If patients wanted the more expensive drug\u2014with no obvious clinical benefit\u2014would that leave a doctor\u2019s prudent decision redundant? All these issues need to be clarified before committing such an ill defined right to legislation.<\/p>\n

Deborah Cohen<\/strong> is investigations editor, BMJ<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

In the midst of his heavy schedule, defending his controversial NHS reforms, Andrew Lansley, health secretary for England,\u00a0has found the time to form a new expert panel which will contribute […]<\/p>\n

More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[116],"tags":[],"class_list":["post-15278","post","type-post","status-publish","format-standard","hentry","category-editors-at-large"],"yoast_head":"\nDeborah Cohen: Access to NICE approved drugs - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Deborah Cohen: Access to NICE approved drugs - The BMJ\" \/>\n<meta property=\"og:description\" content=\"In the midst of his heavy schedule, defending his controversial NHS reforms, Andrew Lansley, health secretary for England,\u00a0has found the time to form a new expert panel which will contribute [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2012-03-09T15:35:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2012-03-09T15:39:03+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.bmj.com\/site\/blog\/icons\/debs.jpg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Deborah Cohen: Access to NICE approved drugs\",\"datePublished\":\"2012-03-09T15:35:58+00:00\",\"dateModified\":\"2012-03-09T15:39:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/\"},\"wordCount\":689,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.bmj.com\\\/site\\\/blog\\\/icons\\\/debs.jpg\",\"articleSection\":[\"Editors at large\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/\",\"name\":\"Deborah Cohen: Access to NICE approved drugs - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.bmj.com\\\/site\\\/blog\\\/icons\\\/debs.jpg\",\"datePublished\":\"2012-03-09T15:35:58+00:00\",\"dateModified\":\"2012-03-09T15:39:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.bmj.com\\\/site\\\/blog\\\/icons\\\/debs.jpg\",\"contentUrl\":\"http:\\\/\\\/www.bmj.com\\\/site\\\/blog\\\/icons\\\/debs.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2012\\\/03\\\/09\\\/deborah-cohen-access-to-nice-approved-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Deborah Cohen: Access to NICE approved drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Deborah Cohen: Access to NICE approved drugs - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/","og_locale":"en_US","og_type":"article","og_title":"Deborah Cohen: Access to NICE approved drugs - The BMJ","og_description":"In the midst of his heavy schedule, defending his controversial NHS reforms, Andrew Lansley, health secretary for England,\u00a0has found the time to form a new expert panel which will contribute [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2012-03-09T15:35:58+00:00","article_modified_time":"2012-03-09T15:39:03+00:00","og_image":[{"url":"http:\/\/www.bmj.com\/site\/blog\/icons\/debs.jpg","type":"","width":"","height":""}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Deborah Cohen: Access to NICE approved drugs","datePublished":"2012-03-09T15:35:58+00:00","dateModified":"2012-03-09T15:39:03+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/"},"wordCount":689,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#primaryimage"},"thumbnailUrl":"http:\/\/www.bmj.com\/site\/blog\/icons\/debs.jpg","articleSection":["Editors at large"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/","url":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/","name":"Deborah Cohen: Access to NICE approved drugs - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#primaryimage"},"thumbnailUrl":"http:\/\/www.bmj.com\/site\/blog\/icons\/debs.jpg","datePublished":"2012-03-09T15:35:58+00:00","dateModified":"2012-03-09T15:39:03+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#primaryimage","url":"http:\/\/www.bmj.com\/site\/blog\/icons\/debs.jpg","contentUrl":"http:\/\/www.bmj.com\/site\/blog\/icons\/debs.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2012\/03\/09\/deborah-cohen-access-to-nice-approved-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Deborah Cohen: Access to NICE approved drugs"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/15278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=15278"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/15278\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=15278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=15278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=15278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}